MedTrace Logo

Pharmacogenetics in Primary Care Psychotropics

NCT03232502 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2017-07-28

No results posted yet for this study

Summary

Pragmatic trial of pharmacogenetic testing at the time of prescription for a selective serotonin reuptake inhibitor, tricyclic antidepressant or atypical antipsychotic. Does real time intervention improve patient outcomes?

Conditions

  • Depression
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder

Interventions

DIAGNOSTIC_TEST

Pharmacogenetic testing

Basic pharmacogenetic panel

Sponsors & Collaborators

  • University of Arizona

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2018-01-15
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03232502 on ClinicalTrials.gov